Trials / Recruiting
RecruitingNCT06918626
INtraoperative Approach With Eventual Clearance of Common bilE Duct by SpyGlass Discover vs Sequential Strategy in Patients With Acute Calculus Cholecystitis and Intermediate/High Risk of Common BiLE Duct Stone
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
INACCESSIBLE trial is a randomized controlled study that compares two different strategies for the treatment of Acute Calculous Cholecystitiis (ACC) patients with high/intermediate risk of CBDS, according to the score by Khoury T (named Israelian Score, IS). If a patient meets the inclusion and exclusion criteria, (s)he will be randomized to receive ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures (control group) or ELC + Spyglass cholangiography (study group). The follow-up will be performed after 30 days and 6 months from intervention with an outpatient medical examination
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | ELC + Spyglass cholangiography | Study group (Spyglass Discover). Patients will undergo ELC surgery as soon as the ACC diagnosis has been confirmed. During surgery, intra-operative cholangiograpy (IOC) will be performed in order to exclude the presence of CBDS and in case of confirmation or still suspicion of CBDS, the exploration of the common bile duct and its eventual clearance via Spyglass Discover is carried out during ELC. |
| PROCEDURE | ERCP + Early Laparoscopic cholecystectomy (ELC) in two stage procedures | Control group (ELC sequential treatment after possible clearance of CBDS via ERCP). Following the diagnosis of ACC, patients with CBDS high/intermediate risk are introduced either directly, in case of high risk, or after performing second-level diagnostics (MNR cholangiography or endoscopic ultrasound), in the case of intermediate risk, to the ERCP with the aim of eliminating CBDS preoperatively and then the ELC will be performed. |
Timeline
- Start date
- 2024-02-18
- Primary completion
- 2025-05-30
- Completion
- 2025-11-30
- First posted
- 2025-04-09
- Last updated
- 2025-04-09
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06918626. Inclusion in this directory is not an endorsement.